Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002110955 | SCV002390352 | likely benign | not provided | 2024-05-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004976236 | SCV005579864 | uncertain significance | Inborn genetic diseases | 2024-07-02 | criteria provided, single submitter | clinical testing | The c.3958C>A (p.L1320I) alteration is located in exon 1 (coding exon 1) of the FAT4 gene. This alteration results from a C to A substitution at nucleotide position 3958, causing the leucine (L) at amino acid position 1320 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004752153 | SCV005348888 | uncertain significance | FAT4-related disorder | 2024-07-29 | no assertion criteria provided | clinical testing | The FAT4 c.3958C>A variant is predicted to result in the amino acid substitution p.Leu1320Ile. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.11% of alleles in individuals of South Asian descent in gnomAD, which may be too common to be causative. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |